10-Q: SelectQuote Q1 Loss Widens, Senior Segment Declines

SelectQuote, Inc. reported a wider net loss attributable to common shareholders in Q1 2026, driven by a significant decline in its Senior insurance segment despite growth in Healthcare Services.

Summary

• Total revenue increased by 13% to $328.8 million for the three months ended September 30, 2025, compared to $292.3 million in the prior year period.
• Net loss attributable to common shareholders widened to $(47.9) million, or $(0.26) per share, from $(44.5) million, or $(0.26) per share, in the same period last year.
• Adjusted EBITDA significantly worsened to $(32.1) million, compared to $(1.7) million in the prior year period.
• The Senior segment's revenue decreased by 37% to $59.0 million, and its Adjusted Segment EBITDA turned negative at $(21.0) million, down from $7.7 million.
• Healthcare Services revenue grew by 42% to $221.4 million, with Adjusted Segment EBITDA increasing by 47% to $7.2 million.
• Life segment revenue increased by 19% to $46.6 million, but its Adjusted Segment EBITDA decreased by 7% to $5.6 million.
• Net cash used in operating activities increased to $(21.6) million from $(16.6) million year-over-year.
• Cash, cash equivalents, and restricted cash decreased to $14.5 million as of September 30, 2025, from $35.7 million as of June 30, 2025.
• Total debt obligations increased to $393.1 million as of September 30, 2025, from $385.1 million as of June 30, 2025.

Sentiment

Score: 3

Explanation: The company reported a significant decline in its core Senior segment, leading to a substantially worse Adjusted EBITDA and increased net cash used in operations. While Healthcare Services shows growth, it's insufficient to offset the overall operational deterioration. The reliance on high-cost preferred stock financing and ongoing legal challenges add considerable financial and operational risk.

Positives

• Healthcare Services segment revenue increased by 42% to $221.4 million, driven by a 24% increase in SelectRx members and a 25.5% increase in prescriptions per day.
• Healthcare Services Adjusted Segment EBITDA increased by 47% to $7.2 million.
• Life segment revenue increased by 19% to $46.6 million, with Term Premiums up 28% and Final Expense Premiums up 20%.
• Interest expense, net, decreased by 49% to $(11.8) million, primarily due to a lower cost of capital from securitization and repayment of $260.0 million of Term Loans using preferred stock proceeds.
• A positive change in the fair value of warrant liabilities contributed $15.0 million to the income statement.

Negatives

• Net loss attributable to common shareholders widened to $(47.9) million from $(44.5) million year-over-year, primarily due to Senior Non-Convertible Preferred Stock accumulated dividends and accretion.
• Adjusted EBITDA significantly worsened to $(32.1) million from $(1.7) million in the prior year period.
• The Senior segment's revenue decreased by 37% to $59.0 million, and its Adjusted Segment EBITDA turned negative at $(21.0) million.
• Approved policies in the Senior segment decreased by 27% to 76,386, and submitted policies decreased by 26%.
• Lifetime Value (LTV) per Medicare Advantage approved policy decreased by 5% to $769.
• Net cash used in operating activities increased to $(21.6) million from $(16.6) million, indicating worsening operational cash burn.
• Cash, cash equivalents, and restricted cash significantly decreased by $21.3 million during the quarter.
• The company is in a three-year cumulative loss position, leading to a valuation allowance of $27.9 million for deferred tax assets.

Risks

• Ongoing securities class action lawsuits alleging securities fraud and misstatements/omissions, which could result in significant damages and legal costs.
• A stockholder derivative action alleging breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets.
• A qui tam action by the U.S. Attorney's Office alleging Federal False Claims Act violations due to improper sales and marketing practices, seeking treble damages and civil penalties.
• A new securities class action (Pahlkotter Action) related to the DOJ Action allegations, seeking unspecified damages and rescission.
• Dependence on a few large insurance carrier customers, with two customers accounting for 44% and 11% of total revenue for the three months ended September 30, 2025.
• Exposure to interest rate risk on variable-rate debt, where a 100 basis point increase would raise annualized interest expense by approximately $3.3 million.
• Seasonality of the Senior segment, with highest revenue in the second and third quarters due to Medicare annual and open enrollment periods, which can impact cash flows.
• Changes in regulations limiting special enrollment period eligibility for Medicare Advantage members, which negatively impacted submitted and approved policies in the Senior segment.

Future Outlook

Management expects existing cash, cash equivalents, funds available under the revolving credit facility, and cash provided from operations to be sufficient to finance normal working capital needs, investments, and debt services for the next 12 months. The company continues to focus on expanding its healthcare services platform, such as SelectRx and SelectPatient Management, while de-emphasizing its Auto & Home distribution business. The company is evaluating the impact of new accounting pronouncements on its financial statements.

Management Comments

• Our strategy is focused on delivering more comprehensive and personalized healthcare solutions that meet the evolving needs of our senior customers.
• We have de-emphasized production within our Auto & Home distribution insurance business, which no longer represents a core area of focus.
• SelectQuote's value lies in our ability to engage the consumer, capture critical self-reported information in real-time, and then take action on that information to offer each consumer personalized solutions.
• We continue to look for more opportunities to leverage our strengths to expand our healthcare services business, whether through acquisitions or new partnerships.
• We believe we will remain in compliance with the debt covenants through the 12 months following the date of issuance of our condensed consolidated financial statements.

Industry Context

The company's strategic shift towards healthcare services, particularly pharmacy and chronic care management, aligns with broader industry trends focusing on integrated patient care and leveraging existing customer bases for cross-selling health-related services. The decline in the Senior segment's performance, particularly Medicare Advantage, may reflect increased competition, regulatory changes impacting enrollment periods, or shifts in carrier strategies within the highly competitive Medicare market. The growth in the Life segment suggests resilience in demand for traditional insurance products despite broader economic pressures.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Securities Class Action (In re SelectQuote, Inc. Securities Litigation): Alleges securities fraud and misstatements/omissions. The court dismissed the second amended complaint on April 3, 2025, but plaintiffs filed a notice of appeal on May 5, 2025. Defendant-appellees brief is due by November 7, 2025.
• Stockholder Derivative Action (Jadlow v. Danker, et al.): Alleges Section 14(a) violations, breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets. This action is currently stayed pending the resolution of the Securities Class Action.
• DOJ Action (United States ex rel. Shea v. eHealth, Inc., et al.): A qui tam action where the U.S. Attorney's Office partially intervened on May 1, 2025. It alleges Federal False Claims Act violations due to improper sales and marketing practices, seeking treble damages, civil penalties, and costs. The Company denies the allegations and plans to defend vigorously. Joint and separate motions to dismiss were filed in August 2025, with government opposition filed in October 2025.
• Pahlkotter Action (Pahlkotter v. SelectQuote, Inc., et al.): A putative securities class action filed on August 11, 2025, related to the allegations in the DOJ Action. It seeks unspecified damages, rescission, and reimbursement of attorneys' fees. The action is currently stayed pending lead plaintiff designation and the filing of an amended complaint.

Related Party Transactions

• SelectRx leases its Monaca facility from an Executive Vice President of SelectRx, with expected total rental payments of $3.6 million over an initial ten-year term plus a five-year extension option.

Stakeholder Impact

• Shareholders: Face increased net losses attributable to common shareholders, significant operational challenges in the Senior segment, and dilution risk from warrants. The high implied interest rate on preferred stock also impacts future earnings available to common shareholders.
• Employees: Compensation costs increased in Life and Healthcare Services, reflecting growth and staffing needs, but overall operational losses could lead to future workforce adjustments.
• Customers: The strategic shift to healthcare services aims to provide more comprehensive solutions, potentially benefiting senior customers with integrated health and pharmacy offerings. However, changes in Medicare regulations could impact policy options.
• Creditors: The company remains in compliance with debt covenants, and interest expense has decreased due to refinancing efforts. However, negative operating cash flow and overall losses indicate ongoing financial strain that could concern lenders.
• Regulatory Authorities: The company is subject to multiple legal and regulatory challenges, including a Federal False Claims Act investigation, which could result in significant penalties and increased scrutiny.

Next Steps

• Continue to defend against multiple ongoing legal proceedings, including securities class actions, a stockholder derivative suit, and a qui tam action by the U.S. Attorney's Office.
• Defendant-appellees brief is due by November 7, 2025, in the appeal of the Securities Class Action.
• Evaluate the impact of new accounting pronouncements (ASU 2023-09 and ASU 2024-03) on future financial statements.
• Potentially redeem up to 50,000 shares of Senior Non-Convertible Preferred Stock between December 1, 2025, and December 31, 2025.
• Issue remaining 15% of Senior Non-Convertible Preferred Stock Warrants on January 2, 2026, unless the Early Redemption Amount is paid by December 31, 2025.

Key Dates

Recommendation

The company's financial performance for the quarter is concerning, marked by a significant decline in its core Senior segment, leading to a substantially worse Adjusted EBITDA and increased net cash used in operations. While the Healthcare Services segment shows growth, it is not enough to offset the overall operational deterioration. The net loss attributable to common shareholders widened, and the company relies on high-cost preferred stock financing (19% implied interest rate) and revolving credit to manage liquidity, indicating financial strain. Multiple ongoing legal proceedings, including a qui tam action by the U.S. Attorney's Office, add significant uncertainty and potential future liabilities. The combination of operational weakness, negative cash flow, high cost of capital, and substantial legal risks makes this a high-risk investment with poor prospects for common shareholders.

Keywords

SelectQuote, SLQT, 10-Q, Quarterly Report, Insurance Distribution, Healthcare Services, Medicare Advantage, Life Insurance, Pharmacy Services, Financial Results, Net Loss, Adjusted EBITDA, Legal Proceedings, Debt, Warrants, Capital Raise